Mark Cutler

6.2k total citations · 2 hit papers
24 papers, 983 citations indexed

About

Mark Cutler is a scholar working on Epidemiology, Infectious Diseases and Microbiology. According to data from OpenAlex, Mark Cutler has authored 24 papers receiving a total of 983 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 9 papers in Infectious Diseases and 7 papers in Microbiology. Recurrent topics in Mark Cutler's work include Pneumonia and Respiratory Infections (10 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Bacterial Infections and Vaccines (7 papers). Mark Cutler is often cited by papers focused on Pneumonia and Respiratory Infections (10 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Bacterial Infections and Vaccines (7 papers). Mark Cutler collaborates with scholars based in United States, United Kingdom and Germany. Mark Cutler's co-authors include David Cooper, Pei‐Yong Shi, Xuping Xie, Kena A. Swanson, Jing Zou, Hongjie Xia, Philip R. Dormitzer, Scott C. Weaver, Camila R. Fontes-Garfias and Yang Liu and has published in prestigious journals such as Nature, Nature Medicine and Nature Communications.

In The Last Decade

Mark Cutler

22 papers receiving 959 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

2021 383 citations Xuping Xie, Yang Liu et al. Nature Medicine profile →
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

2021 212 citations Jianying Liu, Yang Liu et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Cutler United States	13	754	205	148	124	111	24	983
Karin van den Berg South Africa	10	704 0.9×	171 0.8×	106 0.7×	98 0.8×	51 0.5×	45	983
Stephen N. Crooke United States	14	482 0.6×	255 1.2×	53 0.4×	236 1.9×	105 0.9×	34	1.0k
Pieter Neels Belgium	14	224 0.3×	95 0.5×	43 0.3×	133 1.1×	114 1.0×	36	627
Bassam Hallis United Kingdom	17	303 0.4×	257 1.3×	32 0.2×	284 2.3×	87 0.8×	39	961
Peter V. Markov Italy	2	482 0.6×	158 0.8×	63 0.4×	58 0.5×	32 0.3×	5	622
Asmaa Hachim Hong Kong	9	347 0.5×	66 0.3×	49 0.3×	63 0.5×	37 0.3×	13	425
Inesa Hyseni Italy	6	488 0.6×	124 0.6×	66 0.4×	33 0.3×	39 0.4×	6	554
Christine Laurent France	12	382 0.5×	208 1.0×	34 0.2×	172 1.4×	80 0.7×	16	734
Su Hui Catherine Teo Singapore	6	448 0.6×	95 0.5×	40 0.3×	72 0.6×	21 0.2×	8	591

Countries citing papers authored by Mark Cutler

Since Specialization

Citations

This map shows the geographic impact of Mark Cutler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Cutler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Cutler more than expected).

Fields of papers citing papers by Mark Cutler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Cutler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Cutler. The network helps show where Mark Cutler may publish in the future.

Co-authorship network of co-authors of Mark Cutler

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Cutler. A scholar is included among the top collaborators of Mark Cutler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Cutler. Mark Cutler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Martinón‐Torres, Federico, Mika Rämet, Ryan Newton, et al.. (2025). A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix® Vaccine When Given to Healthy Infants at 3 and 12 Months of Age. Infectious Diseases and Therapy. 14(2). 463–481.

Senders, Shelly, Allison Thompson, Mark Cutler, et al.. (2025). Immunogenicity and safety of concomitant vaccines given with 20-valent pneumococcal conjugate vaccine in healthy infants. Vaccine. 68. 127916–127916.

Cutland, Clare, Paula Peyrani, Chris Webber, et al.. (2023). A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12–14-month-old children. Vaccine. 41(5). 1153–1160. 3 indexed citations

Kurhade, Chaitanya, Jing Zou, Hongjie Xia, et al.. (2022). Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nature Communications. 13(1). 3602–3602. 41 indexed citations

Liu, Jianying, Yang Liu, Hongjie Xia, et al.. (2022). BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. npj Vaccines. 7(1). 41–41. 6 indexed citations

Xia, Hongjie, Jing Zou, Chaitanya Kurhade, et al.. (2022). Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. Cell Host & Microbe. 30(4). 485–488.e3. 64 indexed citations

Xie, Xuping, Yang Liu, Jianying Liu, et al.. (2021). Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nature Medicine. 27(4). 620–621. 383 indexed citations breakdown →

Liu, Jianying, Yang Liu, Hongjie Xia, et al.. (2021). BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 596(7871). 273–275. 212 indexed citations breakdown →

Zou, Jing, Xuping Xie, Camila R. Fontes-Garfias, et al.. (2021). The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. npj Vaccines. 6(1). 44–44. 29 indexed citations

10.

Bowman, Christopher, Sarah N. Campion, Gregg D. Cappon, et al.. (2021). Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine. Reproductive Toxicology. 103. 28–35. 55 indexed citations

11.

Borja-Tabora, Charissa, Paula Peyrani, Chris Webber, et al.. (2020). A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years. BMC Infectious Diseases. 20(1). 426–426. 10 indexed citations

12.

Scully, Ingrid L., Mark Cutler, Todd Belanger, et al.. (2019). 1337. Development, Maintenance, and Application of Opsonophagocytic Assays to Measure Functional Antibody Responses to Support a 20 Valent Pneumococcal Conjugate Vaccine. Open Forum Infectious Diseases. 6(Supplement_2). S484–S484. 6 indexed citations

13.

Juergens, Christine, Vani Sundaraiyer, Mark Cutler, et al.. (2017). Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial. Human Vaccines & Immunotherapeutics. 13(9). 2065–2071. 12 indexed citations

14.

Agarkhedkar, Sharad, Christine Juergens, Vani Sundaraiyer, et al.. (2017). Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 6–17 Years of Age in India. The Pediatric Infectious Disease Journal. 36(11). e283–e285. 2 indexed citations

15.

Togashi, Takehiro, Kenji Okada, Allison Thompson, et al.. (2015). Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan. The Pediatric Infectious Disease Journal. 34(10). 1096–1104. 11 indexed citations

16.

Cooper, David, Michael W. Pride, Min Guo, et al.. (2004). Interleukin-12 redirects murine immune responses to soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and CD4 CTL responses. Vaccine. 23(2). 236–246. 19 indexed citations

17.

Ding, Weidong, Girija Krishnamurthy, Ann Aulabaugh, et al.. (1998). Novel and Specific Respiratory Syncytial Virus Inhibitors That Target Virus Fusion. Journal of Medicinal Chemistry. 41(15). 2671–2675. 36 indexed citations

18.

Gao, Bing & Mark Cutler. (1992). Effects of sub-chronic treatment with chlordiazepoxide, buspirone and the 5-HT3 receptor antagonist, BRL 46470, on the social behaviour of mice. Neuropharmacology. 31(3). 207–213. 17 indexed citations

19.

Donald, James M., Megan S. Bradley, J. O’Grady, Mark Cutler, & M. Moore. (1988). Effects of low-level lead exposure on 24 h activity patterns in the mouse. Toxicology Letters. 42(2). 137–147. 9 indexed citations

20.

Donald, James M., Mark Cutler, M. Moore, & Megan S. Bradley. (1986). Effects of lead in the laboratory mouse—2Development and social behaviour after lifelong administration of a small dose of lead acetate in drinking fluid. Neuropharmacology. 25(2). 151–160. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact